Skip to main content
Clinical Trials/JPRN-jRCT1041230068
JPRN-jRCT1041230068
Recruiting
Phase 2

Phase II study of the neoadjuvant chemotherapy of GEM/nab-PTX for biological borderline-resectable pancreatic cancer - NUPAT-10

Ebata Tomoki0 sites50 target enrollmentAugust 9, 2023

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
pancreatic cancer
Sponsor
Ebata Tomoki
Enrollment
50
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 9, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Ebata Tomoki

Eligibility Criteria

Inclusion Criteria

  • 1\) diagnosed as pancreatic cancer by imiging studies
  • 2\) patients without distant metastasis (M0\)
  • 3\) resectable pancreatic cancer
  • 4\) CA19\-9 \>100U/ml
  • 5\) age of 20\-80
  • 6\) PS (ECOG) 0 or 1
  • 7\) initial treatment for the disease
  • 8\) without other malignancies
  • 9\) normal oral ingestion
  • 10\) without major organ failures

Exclusion Criteria

  • 1\) serious allergy for any drug
  • 2\) active other malignancies
  • 3\) active infectious disease
  • 4\) neuropathy (\>Grade 2\)
  • 5\) administered with atanazavir
  • 6\) bowel obstruction or paresis
  • 7\) uncontrolable acites or pleural effusion
  • 8\) uncontrolable diabetes, hypertention, chirrosis, renal failure, ischemic cardiac disease, interstitial pneumonia
  • 9\) pregnant or lactating women
  • 10\) unable to join the clinical trial due to psychological condition

Outcomes

Primary Outcomes

Not specified

Similar Trials